Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PCV13 vaccine

Preclinical

CanSino Biologics Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Streptococcus PneumoniaeRecruiting

Streptococcus PneumoniaePreclinical

Recruiting

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Streptococcus Pneumoniae

NCT07600983

Clinical

Trials by Indication[1]

Streptococcus Pneumoniae1 trial

A Randomized, Blinded, Dose-Exploratory, Positive-Control Clinical Trial Evaluating the Safety and Immunogenicity of the 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) Following Administration in Individuals Aged 2 Months (Minimum 6 Weeks) and Older

Recruiting· CanSino Biologics Inc. logo

CanSino Biologics Inc.·Preclinical·NCT07600983·854 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PCV13 vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for PCV13 vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — CanSino Biologics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: CanSino Biologics Inc.

Related News